Proactive Investors - Run By Investors For Investors

OptiBiotix extends LPLDL supply agreement with German probiotics firm HLH

Under the terms of the new deal, HLH will have to double its order volume every year for three years if it wants to maintain exclusivity over LPLDL in Germany
HLH is one of Europe’s leading suppliers of probiotics to the pharmacy market

OptiBiotix Health plc’s (LON:OPTI) subsidiary, ProBiotix Health, has extended its original supply agreement with German probiotics supplier HLH Biopharma.

The new three-year agreement grants HLH an exclusive licence to produce, package and commercialise a capsule containing Opti’s cholesterol-reducing LPLDL strain in Germany.

In order to maintain exclusivity in Germany, HLH will have to double its order volumes every year.

READ: OptiBiotix Health’s cholesterol product recognised as safe by expert US panel

As part of the tie-up, HLH has also been granted a non-exclusive licence to produce, package and commercialise products containing LPLDL in Austria, Switzerland and the United Arab Emirates.

“We are pleased to announce this extension of terms and territory with HLH who is one of Europe's leading suppliers of probiotics to the pharmacy market,” said chief executive Stephen O’Hara.

“The agreement recognises the success of HLH in building sales of its LPLDL containing Lactobact brand in Germany and extends the terms and territory to support further sale growth.

“This is another step in extending the geographical reach of LPLDL as it builds recurring revenue streams and increases brand recognition and the value of its products.

“This is part of a strategy which allows OptiBiotix to present customised product solutions through its partners to consumer health, pharmaceutical and retail companies around the world.”

View full OPTI profile View Profile

OptiBiotix Health PLC Timeline

Related Articles

CBD oil
November 15 2018
The company’s technology creates nano-scale emulsion mixtures that allow fluids to mix that normally don’t mix, such as CBD oil and water
cancer scan
January 03 2019
The company, which owns a piece of software which predicts the effects of drugs on cancers, has recently extended a lucrative agreement with German firm Merck Serono while it has also signed a strategic collaboration with the Medicines Discovery Catapult
scientist looking through microscope
April 11 2018
Kumaraguru Raja sees “multiple catalysts” in the year ahead which could put a rocket under the share price

© Proactive Investors 2019

Proactive Investors Limited, trading as “Proactiveinvestors United Kingdom”, is Authorised and regulated by the Financial Conduct Authority.
Registered in England with Company Registration number 05639690. Group VAT registration number 872070825 FCA Registration number 559082. You can contact us here.

Market Indices, Commodities and Regulatory News Headlines copyright © Morningstar. Data delayed 15 minutes unless otherwise indicated. Terms of use